ArticlePatient preference and adherence2026
Comprehensive Pharmaceutical Care and Service-Related Outcomes During Vonoprazan-Amoxicillin Dual Therapy in Elderly Patients: A Retrospective Cohort Study.
Article in Patient preference and adherence, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study evaluated the potential association between clinical pharmacist-led comprehensive pharmaceutical care and treatment outcomes in elderly patients receiving initial vonoprazan-amoxicillin dual therapy for Helicobacter pylori infection. Methods: In this single-center retrospective cohort study, a total of 100 elderly patients (≥65 years) with H. pylori infection who received initial eradication therapy between May 2023 and May 2025 were included. Based on the level of pharmaceutical care provided during treatment, patients were classified into a control group (n=50, receiving standard medication counseling) or an observation group (n=50, receiving multi-stage, pharmacist-led comprehensive pharmaceutical care). Outcomes included adverse events, H. pylori eradication rate, medication adherence, and patient satisfaction. Results: The incidence of adverse events was lower in the observation group than in the control group (12.0% vs 30.0%, P=0.027). The H. pylori eradication rate was numerically higher in the observation group (84.0% vs 74.0%, P=0.220). Medication adherence was significantly better in the observation group than in the control group (P<0.001). Overall patient satisfaction was also higher in the observation group than in the control group (86.0% vs 60.0%, P=0.007). Conclusion: Comprehensive pharmaceutical care during dual therapy for H. pylori infection in elderly patients was associated with fewer adverse events and improved medication adherence and patient satisfaction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.